These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 20880776)

  • 1. Non-conventional imaging of lung cancer.
    Bellomi M
    Cancer Imaging; 2010 Oct; 10 Spec no A(1A):S161-2. PubMed ID: 20880776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diffusion-weighted MR imaging in comparison to integrated [¹⁸F]-FDG PET/CT for N-staging in patients with lung cancer.
    Pauls S; Schmidt SA; Juchems MS; Klass O; Luster M; Reske SN; Brambs HJ; Feuerlein S
    Eur J Radiol; 2012 Jan; 81(1):178-82. PubMed ID: 20932700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
    Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
    Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diffusion-weighted MR imaging using FASE sequence for 3T MR system: Preliminary comparison of capability for N-stage assessment by means of diffusion-weighted MR imaging using EPI sequence, STIR FASE imaging and FDG PET/CT for non-small cell lung cancer patients.
    Ohno Y; Koyama H; Yoshikawa T; Takenaka D; Kassai Y; Yui M; Matsumoto S; Sugimura K
    Eur J Radiol; 2015 Nov; 84(11):2321-31. PubMed ID: 26231045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 18F-FDG PET/CT and whole-body MRI diagnostic performance in M staging for non-small cell lung cancer: a systematic review and meta-analysis.
    Machado Medeiros T; Altmayer S; Watte G; Zanon M; Basso Dias A; Henz Concatto N; Hoefel Paes J; Mattiello R; de Souza Santos F; Mohammed TL; Verma N; Hochhegger B
    Eur Radiol; 2020 Jul; 30(7):3641-3649. PubMed ID: 32125513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of bone metastases in non-small cell lung cancer patients: comparison of whole-body diffusion-weighted imaging (DWI), whole-body MR imaging without and with DWI, whole-body FDG-PET/CT, and bone scintigraphy.
    Takenaka D; Ohno Y; Matsumoto K; Aoyama N; Onishi Y; Koyama H; Nogami M; Yoshikawa T; Matsumoto S; Sugimura K
    J Magn Reson Imaging; 2009 Aug; 30(2):298-308. PubMed ID: 19629984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the Added Value of Diffusion-Weighted Imaging to Conventional Magnetic Resonance Imaging in Pancreatic Neuroendocrine Tumors and Comparison With 68Ga-DOTANOC Positron Emission Tomography/Computed Tomography.
    Farchione A; Rufini V; Brizi MG; Iacovazzo D; Larghi A; Massara RM; Petrone G; Poscia A; Treglia G; De Marinis L; Giordano A; Rindi G; Bonomo L
    Pancreas; 2016 Mar; 45(3):345-54. PubMed ID: 26418904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic value of diffusion-weighted magnetic resonance imaging (DWI) compared to FDG PET/CT for whole-body breast cancer staging.
    Heusner TA; Kuemmel S; Koeninger A; Hamami ME; Hahn S; Quinsten A; Bockisch A; Forsting M; Lauenstein T; Antoch G; Stahl A
    Eur J Nucl Med Mol Imaging; 2010 Jun; 37(6):1077-86. PubMed ID: 20204355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recurrence and metastasis of lung cancer demonstrate decreased diffusion on diffusion-weighted magnetic resonance imaging.
    Usuda K; Sagawa M; Motomo N; Ueno M; Tanaka M; Machida Y; Maeda S; Matoba M; Tonami H; Ueda Y; Sakuma T
    Asian Pac J Cancer Prev; 2014; 15(16):6843-8. PubMed ID: 25169535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imaging the early response to chemotherapy in advanced lung cancer with diffusion-weighted magnetic resonance imaging compared to fluorine-18 fluorodeoxyglucose positron emission tomography and computed tomography.
    Tsuchida T; Morikawa M; Demura Y; Umeda Y; Okazawa H; Kimura H
    J Magn Reson Imaging; 2013 Jul; 38(1):80-8. PubMed ID: 23239463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hybrid [¹⁸F]-FDG PET/MRI including non-Gaussian diffusion-weighted imaging (DWI): preliminary results in non-small cell lung cancer (NSCLC).
    Heusch P; Köhler J; Wittsack HJ; Heusner TA; Buchbender C; Poeppel TD; Nensa F; Wetter A; Gauler T; Hartung V; Lanzman RS
    Eur J Radiol; 2013 Nov; 82(11):2055-60. PubMed ID: 23830904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment Response Evaluation of Breast Cancer after Neoadjuvant Chemotherapy and Usefulness of the Imaging Parameters of MRI and PET/CT.
    An YY; Kim SH; Kang BJ; Lee AW
    J Korean Med Sci; 2015 Jun; 30(6):808-15. PubMed ID: 26028936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MRI in lung cancer: a pictorial essay.
    Hochhegger B; Marchiori E; Sedlaczek O; Irion K; Heussel CP; Ley S; Ley-Zaporozhan J; Soares Souza A; Kauczor HU
    Br J Radiol; 2011 Jul; 84(1003):661-8. PubMed ID: 21697415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of multifocality and axillary nodal involvement in early-stage breast cancer patients using 18F-FDG PET/CT compared to contrast-enhanced and diffusion-weighted magnetic resonance imaging and sentinel node biopsy.
    Ergul N; Kadioglu H; Yildiz S; Yucel SB; Gucin Z; Erdogan EB; Aydin M; Muslumanoglu M
    Acta Radiol; 2015 Aug; 56(8):917-23. PubMed ID: 25013091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Newly diagnosed lymphoma: initial results with whole-body T1-weighted, STIR, and diffusion-weighted MRI compared with 18F-FDG PET/CT.
    van Ufford HM; Kwee TC; Beek FJ; van Leeuwen MS; Takahara T; Fijnheer R; Nievelstein RA; de Klerk JM
    AJR Am J Roentgenol; 2011 Mar; 196(3):662-9. PubMed ID: 21343511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of diffusion-weighted MRI and (18)F-FDG PET/CT in the prediction of pathologic complete response after radiochemotherapy for rectal cancer: a systematic review.
    Joye I; Deroose CM; Vandecaveye V; Haustermans K
    Radiother Oncol; 2014 Nov; 113(2):158-65. PubMed ID: 25483833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system.
    Schmidt H; Brendle C; Schraml C; Martirosian P; Bezrukov I; Hetzel J; Müller M; Sauter A; Claussen CD; Pfannenberg C; Schwenzer NF
    Invest Radiol; 2013 May; 48(5):247-55. PubMed ID: 23519008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative mediastinal and hilar nodal staging with diffusion-weighted magnetic resonance imaging and fluorodeoxyglucose positron emission tomography/computed tomography in patients with non-small-cell lung cancer: which is better?
    Wu LM; Xu JR; Gu HY; Hua J; Chen J; Zhang W; Haacke EM; Hu J
    J Surg Res; 2012 Nov; 178(1):304-14. PubMed ID: 22541065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Whole-body staging of malignant melanoma: advantages, limitations and current importance of PET-CT, whole-body MRI and PET-MRI].
    Pfannenberg C; Schwenzer N
    Radiologe; 2015 Feb; 55(2):120-6. PubMed ID: 25589421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal imaging protocols for lung cancer staging: CT, PET, MR imaging, and the role of imaging.
    Paul NS; Ley S; Metser U
    Radiol Clin North Am; 2012 Sep; 50(5):935-49. PubMed ID: 22974779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.